PFIZER2020-04-012020-06-30in-bse-fin:OneOperatingExpenses01Member PFIZER2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares PFIZER 2020-04-01 2021-03-31 2020-07-17 INR Crores First quarter Single segment Pharmaceuticals 2020-04-01 2020-06-30 Unaudited Standalone 5148900000.00 172000000.00 5320900000.00 733000000.00 1219600000.00 -176700000.00 859000000.00 30100000.00 271400000.00 651100000.00 3587500000.00 1733400000.00 0.00 1733400000.00 500400000.00 -11500000.00 488900000.00 0.00 1244500000.00 0.00 0.00 0.00 0.00 1244500000.00 -22000000.00 1222500000.00 0.00 0.00 457500000.00 10 27.20 27.20 0.00 0.00 27.20 27.20 1.The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on 27 July 2020 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. n n2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As amended) and SEBI circular dated July 5, 2016. n n3.The financial results for period ended 30 June 2020 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerindia.com n n4.Figures for the quarter ended 31 March 2020 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and published year to date figures up to the third quarter of the financial year. Also, the figures up to the end of the third quarter were only reviewed and not subjected to audit. n n5.The Company has only one segment which is ‘Pharmaceuticals’. Therefore, disclosure relating to segments is not applicable and accordingly not made. n n6.The COVID-19 pandemic and consequent Nationwide lockdown have impacted regular business operations. The Company has monitored the impact of COVID-19 on all aspects of its business. The management has exercised due care, in concluding on significant accounting judgments and estimates, recoverability of receivables, assessment for impairment of goodwill, intangible assets, inventory based on the information available as on date, while preparing the financial results. n nIn view of the continued uncertainties and its inability to predict the extend and duration of COVID-19 situation, the Company currently is unable to predict any future impact on its business operations. The Company will continue to ensure supply of essential medicines and take steps to mitigate any risks associated with COVID-19 pandemic. Other Expenses 651100000.00